Sexually Dimorphic Effects of Catechol-O-Methyltransferase (COMT) Inhibition on Dopamine Metabolism in Multiple Brain Regions

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Laatikainen, Linda M ^a   Sharp, Trevor ^a   Harrison, Paul J ^a   Tunbridge, Elizabeth M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; CATECHOL METHYLTRANSFERASE; HOMOVANILLIC ACID; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOWN REGULATION; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; HIPPOCAMPUS; MALE; METABOLIC INHIBITION; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; PREFRONTAL CORTEX; RAT; SEX DIFFERENCE; UPREGULATION;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BENZOPHENONES; BRAIN; CATECHOL O-METHYLTRANSFERASE; CEREBELLUM; DOPAMINE; FEMALE; HIPPOCAMPUS; MALE; NITROPHENOLS; PREFRONTAL CORTEX; RATS; SEX FACTORS;

RATTUS;

EID: 84876188924     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061839     Document Type: Article

References (48)

1. Tunbridge EM, Bannerman DM, Sharp T, Harrison PJ, (2004) Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci 24: 5331-5335.
2. Yavich L, Forsberg MM, Karayiorgou M, Gogos JA, Mannisto PT, (2007) Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J Neurosci 27: 10196-10209.
3. Lapish CC, Ahn S, Evangelista LM, So K, Seamans JK, et al. (2009) Tolcapone enhances food-evoked dopamine efflux and executive memory processes mediated by the rat prefrontal cortex. Psychopharmacology (Berl) 202: 521-530.
4. Kaenmaki M, Tammimaki A, Myohanen T, Pakarinen K, Amberg C, et al. (2010) Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. J Neurochem 114: 1745-1755.
5. Mannisto PT, Kaakkola S, (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51: 593-628.
6. Ceravolo R, Piccini P, Bailey DL, Jorga KM, Bryson H, et al. (2002) 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 43: 201-207.
7. Zurcher G, Keller HH, Kettler R, Borgulya J, Bonetti EP, et al. (1990) Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. Adv Neurol 53: 497-503.
8. Acquas E, Carboni E, de Ree RH, Da Prada M, Di Chiara G, (1992) Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592. J Neurochem 59: 326-330.
9. Maj J, Rogoz Z, Skuza G, Sowinska H, Superata J, (1990) Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease. J Neural Transm Park Dis Dement Sect 2: 101-112.
10. Li YH, Wirth T, Huotari M, Laitinen K, MacDonald E, et al. (1998) No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats. Eur J Pharmacol 356: 127-137.
11. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, et al. (1998) Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A 95: 9991-9996.
12. Huotari M, Gogos JA, Karayiorgou M, Koponen O, Forsberg M, et al. (2002) Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci 15: 246-256.
13. Goldman-Rakic PS, Muly EC 3rd, Williams GV, (2000) D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 31: 295-301.
14. Liljequist R, Haapalinna A, Ahlander M, Li YH, Mannisto PT, (1997) Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. Behav Brain Res 82: 195-202.
15. Papaleo F, Crawley JN, Song J, Lipska BK, Pickel J, et al. (2008) Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J Neurosci 28: 8709-8723.
16. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, et al. (2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 98: 6917-6922.
17. Barnett JH, Heron J, Ring SM, Golding J, Goldman D, et al. (2007) Gender-specific effects of the catechol-O-methyltransferase Val108/158Met polymorphism on cognitive function in children. Am J Psychiatry 164: 142-149.
18. Tunbridge EM, Harrison PJ, Weinberger DR, (2006) Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 60: 141-151.
19. Mier D, Kirsch P, Meyer-Lindenberg A, (2010) Neural substrates of pleiotropic action of genetic variation in COMT: a meta-analysis. Mol Psychiatry 15: 918-927.
20. Farrell SM, Tunbridge EM, Braeutigam S, Harrison PJ, (2012) COMT Val(158)Met Genotype Determines the Direction of Cognitive Effects Produced by Catechol-O-Methyltransferase Inhibition. Biol Psychiatry 71: 538-544.
21. Giakoumaki SG, Roussos P, Bitsios P, (2008) Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. Neuropsychopharmacology 33: 3058-3068.
22. Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, et al. (2007) Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 32: 1011-1020.
23. Matsumoto M, Weickert CS, Akil M, Lipska BK, Hyde TM, et al. (2003) Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function. Neuroscience 116: 127-137.
24. Laatikainen L, Sharp T, Bannerman D, Harrison P, Tunbridge E, (2012) Modulation of hippocampal dopamine metabolism and hippocampal-dependent cognitive function by catechol-O-methyltransferase inhibition. J Psychopharmacol.
25. Schott BH, Seidenbecher CI, Fenker DB, Lauer CJ, Bunzeck N, et al. (2006) The dopaminergic midbrain participates in human episodic memory formation: evidence from genetic imaging. J Neurosci 26: 1407-1417.
26. Bertolino A, Rubino V, Sambataro F, Blasi G, Latorre V, et al. (2006) Prefrontal-hippocampal coupling during memory processing is modulated by COMT val158met genotype. Biol Psychiatry 60: 1250-1258.
27. Drabant EM, Hariri AR, Meyer-Lindenberg A, Munoz KE, Mattay VS, et al. (2006) Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation. Arch Gen Psychiatry 63: 1396-1406.
28. Bilder RM, Volavka J, Lachman HM, Grace AA, (2004) The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 29: 1943-1961.
29. Yacubian J, Sommer T, Schroeder K, Glascher J, Kalisch R, et al. (2007) Gene-gene interaction associated with neural reward sensitivity. Proc Natl Acad Sci U S A 104: 8125-8130.
30. Tunbridge EM, Huber A, Farrell SM, Stumpenhorst K, Harrison PJ, et al. (2012) The role of catechol-o-methyltransferase in reward processing and addiction. CNS Neurol Disord Drug Targets 11: 306-323.
31. Berridge KC, Robinson TE, (1998) What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28: 309-369.
32. Gan JO, Walton ME, Phillips PE, (2010) Dissociable cost and benefit encoding of future rewards by mesolimbic dopamine. Nat Neurosci 13: 25-27.
33. Tunbridge EM, Harrison PJ, (2011) Importance of the COMT gene for sex differences in brain function and predisposition to psychiatric disorders. Curr Top Behav Neurosci 8: 119-140.
34. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, et al. (2003) COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299: 1240-1243.
35. Westerink BH, Korf J, (1975) Influence of drugs on striatal and limbic homovanillic acid concentration in the rat brain. Eur J Pharmacol 33: 31-40.
36. Chen J, Song J, Yuan P, Tian Q, Ji Y, et al. (2011) Orientation and cellular distribution of membrane-bound catechol-O-methyltransferase in cortical neurons: implications for drug development. J Biol Chem 286: 34752-34760.
37. Myohanen TT, Schendzielorz N, Mannisto PT, (2010) Distribution of catechol-O-methyltransferase (COMT) proteins and enzymatic activities in wild-type and soluble COMT deficient mice. J Neurochem 113: 1632-1643.
38. Wittmann BC, Schott BH, Guderian S, Frey JU, Heinze HJ, et al. (2005) Reward-related FMRI activation of dopaminergic midbrain is associated with enhanced hippocampus-dependent long-term memory formation. Neuron 45: 459-467.
39. Packard MG, White NM, (1989) Memory facilitation produced by dopamine agonists: role of receptor subtype and mnemonic requirements. Pharmacol Biochem Behav 33: 511-518.
40. Goto Y, Grace AA, (2008) Dopamine modulation of hippocampal-prefrontal cortical interaction drives memory-guided behavior. Cereb Cortex 18: 1407-1414.
41. Bannerman DM, Rawlins JN, McHugh SB, Deacon RM, Yee BK, et al. (2004) Regional dissociations within the hippocampus-memory and anxiety. Neurosci Biobehav Rev 28: 273-283.
42. Enoch MA, Xu K, Ferro E, Harris CR, Goldman D, (2003) Genetic origins of anxiety in women: a role for a functional catechol-O-methyltransferase polymorphism. Psychiatr Genet 13: 33-41.
43. Pooley EC, Fineberg N, Harrison PJ, (2007) The met(158) allele of catechol-O-methyltransferase (COMT) is associated with obsessive-compulsive disorder in men: case-control study and meta-analysis. Mol Psychiatry.
44. Sesack SR, Hawrylak VA, Guido MA, Levey AI, (1998) Cellular and subcellular localization of the dopamine transporter in rat cortex. Adv Pharmacol 42: 171-174.
45. Lewis DA, Melchitzky DS, Sesack SR, Whitehead RE, Auh S, et al. (2001) Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization. J Comp Neurol 432: 119-136.
46. Budygin EA, Gainetdinov RR, Kilpatrick MR, Rayevsky KS, Mannisto PT, et al. (1999) Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake. Eur J Pharmacol 370: 125-131.
47. Stumpenhorst K, Käenmäki M, Harrison PJ, Sharp T, Tunbridge EM, (2012) Catechol-O-methyltransferase (COMT) inhibition and D-9-tetrahydrocannabinol (THC) have interactive effects on dopamine levels in the nucleus accumbens. J Psychopharm 26: A64.
48. Jorga K, Fotteler B, Banken L, Snell P, Steimer JL, (2000) Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. Br J Clin Pharmacol 49: 39-48.